PSMA PET/CT在前列腺癌根治术后挽救性放疗初始反应评估中的作用
本研究回顾性分析194例机器人辅助腹腔镜根治性前列腺切除术后生化复发、PSMA PET/CT无转移证据并接受挽救性放疗的患者,评估短期肿瘤学结局的预测因素。总体治疗反应率为75%(146/194),多因素分析显示挽救性放疗启动时PSA值、病理T分期及影像学局部复发疾病是治疗反应的预测因素。
要点
- PSMA PET/CT无转移证据者挽救性放疗总体反应率75%。
- 挽救性放疗启动时PSA越低,治疗反应率越高。
- 影像学局部复发疾病与更高治疗反应率相关。
核心结论
- PSMA PET/CT无转移证据的患者接受挽救性放疗总体治疗反应率为75%。
- 挽救性放疗启动时PSA值较低、影像学局部复发疾病及较低病理T分期(pT2 vs pT3a/b)与更高治疗反应率相关。
研究设计与样本
- 回顾性分析194例机器人辅助腹腔镜根治性前列腺切除术后生化复发、PSMA PET/CT无转移证据并接受挽救性放疗的患者。
- 排除再分期影像或扩大盆腔淋巴结清扫时发现淋巴结或远处转移者,以及挽救性放疗期间或之前接受雄激素剥夺治疗者。
- 采用多因素逻辑回归分析评估治疗反应(挽救性放疗后PSA≤0.1 ng/ml)的预测因素。
主要发现
- 挽救性放疗后总体治疗反应率为75%(146/194例)。
- 多因素分析中,挽救性放疗启动时PSA值(OR 0.42,95%CI 0.27-0.62,p<0.001)为治疗反应的预测因素。
- 病理T分期pT3a vs pT2(OR 0.28,95%CI 0.11-0.69,p=0.006)和pT3b vs pT2(OR 0.26,95%CI 0.09-0.71,p=0.009)为治疗反应的预测因素。
- 影像学局部复发疾病(OR 5.53,95%CI 1.96-18.52,p=0.003)为治疗反应的预测因素。
关键数值与推荐
- 治疗反应定义为挽救性放疗后PSA值≤0.1 ng/ml。
- 总体治疗反应率为75%(146/194例)。
临床怎么用
- 对于PSMA PET/CT无转移证据的根治性前列腺切除术后生化复发患者,挽救性放疗前应关注PSA值、病理T分期及影像学局部复发情况以预测治疗反应。
- 挽救性放疗启动时PSA较低、影像学显示局部复发且病理T分期较低的患者可能获得更高治疗反应率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed predictors of short-term oncologic outcomes of patients who underwent salvage radiation therapy for biochemical recurrence after robot-assisted laparoscopic radical prostatectomy without evidence of metastases on prostate specific membrane antigen positron emission tomography/computerized tomography. MATERIALS AND METHODS: We retrospectively analyzed 194 patients with biochemical recurrence after robot-assisted laparoscopic radical prostatectomy who underwent prostate specific membrane antigen positron emission tomography/computerized tomography prior to salvage radiation therapy. Patients with lymph node or distant metastases on restaging imaging or at the time of extended pelvic lymph node dissection during robot-assisted laparoscopic radical prostatectomy were excluded, as were patients who received androgen deprivation therapy during or prior to salvage radiation therapy. A multivariable logistic regression analysis was performed to assess predictors of treatment response, defined as prostate specific antigen value ≤0.1 ng/ml after salvage radiation therapy. RESULTS: Overall treatment response after salvage radiation therapy was 75% (146/194 patients). On multivariable analysis, prostate specific antigen value at initiation of salvage radiation therapy (OR 0.42, 95% CI 0.27-0.62, p <0.001), pathological T stage (pT3a vs pT2 OR 0.28, 95% CI 0.11-0.69, p=0.006; pT3b vs pT2 OR 0.26, 95% CI 0.09-0.71, p=0.009) and local recurrent disease on imaging (OR 5.53, 95% CI 1.96-18.52, p=0.003) were predictors of treatment response. CONCLUSIONS: Salvage radiation therapy in patients without evidence of metastases on prostate specific membrane antigen positron emission tomography/computerized tomography showed a good overall treatment response of 75%. Higher treatment response rates were observed in patients with lower prostate specific antigen values at initiation of salvage radiation therapy, those with local recurrent disease on imaging and those with lower pathological T stage (pT2 vs pT3a/b).
引用
- Meijer D, Luiting HB, van Leeuwen PJ, et al. Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. J Urol. 2020. PMID: 33207138. doi:10.1097/JU.0000000000001437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。